Views on glucocorticoid therapy in rheumatology: the age of convergence

  title={Views on glucocorticoid therapy in rheumatology: the age of convergence},
  author={Frank Buttgereit},
  journal={Nature Reviews Rheumatology},
  • F. Buttgereit
  • Published 19 February 2020
  • Medicine, Biology
  • Nature Reviews Rheumatology
After decades of sometimes fierce debate about the advantages and disadvantages of glucocorticoids, an age of convergence has been reached. Current recommendations for the management of diseases such as rheumatoid arthritis (RA), polymyalgia rheumatica and large vessel vasculitis reflect the current consensus that as much glucocorticoid as necessary, but as little as possible, should be used. Over the past few years, a range of glucocorticoid-sparing strategies have been developed, as have… 

Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica

Questions remain about the best treatment regimens and biomarkers to monitor disease activity and predict flare after discontinuation of treatment, including the tapering of treatment for giant cell arteritis and polymyalgia rheumatica.

Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis

GC treatment in LVV is effective but associated with toxicity, so strategies to minimize this toxicity should be applied when treating patients suffering from LVV.

Effect of glucocorticoids combined with disease modifying anti-rheumatic drugs on the improvement of symptoms in patients with rheumatoid arthritis

The combination of glucocorticoids and disease modifying anti-rheumatic drugs in the treatment of patients with rheumatoid arthritis is safe can further improve their symptoms and serological indexes, and will not lead to increased adverse reactions.

Applications of Corticosteroid Therapy in Inflammatory Rheumatic Diseases

The main characteristics of the glucocorticoids, their mechanism of action and effects on the immune system given the fact that they reduce the activation, proliferation, differentiation and survival of inflammatory cells such as macrophages and lymphocytes are discussed.

Patients' and rheumatologists' perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis-an international survey within the GLORIA study.

There is an unmet need for appropriately designed prospective trials that shed light on the real risk associated with low-dose GCs, as well as a need for renovated educational programs on thereal benefits and harms of low-drugs, for both patients and physicians.

Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease

GCs of ≤5 mg/day did not seem to be associated with a reduction of BMD in patients with iRMD and current or prior exposure to GC, most likely due to the dampening of inflammation by GC, which exerts a mitigating effect on the risk of OP.

Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitides—Cross-Sectional Baseline Analysis of the Prospective Rh-GIOP Cohort

In this cohort of PMR and vasculitides, a similar prevalence of OP by DXA to the overall elderly German population is found and proton-pump inhibitors seem to be a major, but somewhat neglected, risk factor for OP and should be given more attention.

Renal disorders in rheumatologic diseases: the spectrum is changing (part 2. Arthridides)

This review is devoted to rheumatologic diseases mainly characterized by different types of arthritis. They may involve also different organs, including the kidney, but renal disease is more

Inflammatory Diseases of the Aorta: JACC Focus Seminar, Part 2.

Bone Involvement in Systemic Lupus Erythematosus

This review aims to highlight bone manifestations in SLE patients, deepening underlying etiopathogenetic mechanisms, diagnostic tools and available treatment, and to improve the survival of SLE patient, increasing long-term morbidities, including osteoporosis and related fractures.



Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis?

The current view on these drugs is that they are indispensable; however, they should be administered as much as necessary but as little as possible; and the more effective the treatment is with DMARDs, the lower can be the GC dosages.

Glucocorticoids in rheumatoid arthritis: the picture is shaping up

The view on the most optimal use of these drugs does slowly but constantly maturate, which primarily results from thorough analyses of accumulated data in order to update recommendations, but there are also new and often qualitatively better data coming in to enrich the authors' knowledge.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Recommendations are intended to inform rheumatologists, patients and other stakeholders about a European consensus on the management of RA with DMARDs and GCs as well as strategies to reach optimal outcomes of RA based on evidence and expert opinion.

Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis

Current approaches to achieve an optimized application of conventional glucocorticoids and the development of novel formulations aiming at minimizing adverse effects while keeping or even enhancing the anti-inflammatory efficacy are discussed.

Safety of Glucocorticoids in Rheumatoid Arthritis: Evidence from Recent Clinical Trials

Toxicity data obtained in randomized clinical trials of low-dose glucocorticoid in rheumatoid arthritis is reviewed, given that observational studies cannot guarantee the avoidance of bias by indication.

Will we ever have better glucocorticoids?

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

The 2010 European League against Rheumatism recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and b DMARDs, respectively) have been updated and are intended to improve outcome in patients with RA.

Effects of glucocorticoids on radiological progression in rheumatoid arthritis.

Even in the most conservative estimate, the evidence that glucocorticoids given in addition to standard therapy can substantially reduce the rate of erosion progression in rheumatoid arthritis is convincing.

Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort

This 7-year analysis of the ESPOIR cohort supports the good safety profile of very low-dose GC for early active RA, which shows greater use of non-steroidal anti-inflammatory drugs, synthetic and biological disease-modifying antirheumatic drugs and had more active disease disability.

2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative

Eight overarching principles and nine specific recommendations were developed covering several aspects of PMR, including basic and follow-up investigations of patients under treatment, risk factor assessment, medical access for patients and specialist referral, treatment strategies such as initial glucocorticoid doses and subsequent tapering regimens, and the roles of non-steroidal anti-rheumatic drugs and non-pharmacological interventions.